### TRAVEL AND CONFERENCE SUPPORT

##### NIH -- TASK ORDER

###### TASK ORDER \# NTCS- \_\_\_\_\_\_\_\_\_\_\_\_\_\_-\_\_\_\_\_\_

####### PART I -- INITIATOR'S REQUEST

A.  **INITIATOR**: J. Silvio Gutkind, Ph.D.

> **Phone:** 301-496-3695 **Fax:** 301-402-0823
>
> **Address:** 30 Convent Drive, Bldg. 30, Rm. 211
>
> Bethesda, MD 20892-4340
>
> **Agency-Billing Address:**
>
> Accounts Payable, OFM, NIH
>
> Bldg. 31, Room B1B39
>
> Bethesda, MD 20892-2045

B.  **PROPOSED PERIOD OF PERFORMANCE:**

> August 29, 2007 through August 28, 2008

C.  **TASK DESCRIPTION:**

> Payments to Dr. Kantima Leelahavanichkul as travel and perdiem from
> the Faculty of Dentistry, Thammasat University, Thailand, during her
> stay at OPCB from August 29, 2007 -- through -- August 28, 2008
>
> A total of \$25,000 to be paid to Dr. Leelahavanichkul in 12 payments:
> September 15, 2007 - \$2,500, October 15, 2007 - July 15, 2008 -
> \$2,000, August 15, 2008 - \$2,500. Please send payments by FedEx or
> express mail to NIDCR/NIH, 30 Convent Drive Room 508, Bethesda,
> Maryland 20892. Attention Lidia Caraballo.

**[Personal Information]{.underline}**

> Dr. Kantima Leelahavanichkul
>
> 10500 Rockville Pike Unit 1508
>
> Rockville, MD 20852

D.  RESPONSE DUE DATE: July 2, 2007

## 

## **STATEMENT OF WORK**

> 1\. [Objectives]{.underline}
>
> The contractor will provide Dr. Silvio Gutkind with professional
> laboratory services. Dr. Kantima Leelahavanichkul's work will focus on
> studying the molecular mechanisms of signal transduction pathways that
> are deregulated in squamous cell carcinomas of the oral cavity. In
> particular, she will examine the contribution of the PI3K-Akt pathway
> to the neoplastic conversion of epithelial cells.
>
> 2\. [Approach]{.underline}
>
> > The contractor will work using transient and stable transfections
> > into murine and human epithelial cells, and engineer transgenic
> > animal lines to express genes under the control of an inducible
> > system to evaluate the contribution of signaling pathways to
> > oncogenesis.
>
> 3\. [Methods]{.underline}
>
> The services that will be performed are as follows.
>
> a\) The contractor will test the function of genes using cloning
> techniques, western blots, northern blots and basic molecular cell
> biology techniques relative to the projects.

b\) The advance techniques will be: Using engineered mice, laser-capture
microdissection, gene arrays, and antibody arrays.

> c\) Keeping careful records of all experiments that were performed.

# Personnel, evaluation and schedule

A.  [Personnel]{.underline}

> The contractor is an expert in primary cell preparations and has
> extensive experience in analytic methodologies with emphasis on those
> used to study carcinogenesis. Personnel provided under the contract
> will comply with the rules and policies of the NIDCR and its staff.

B.  [Evaluation]{.underline}

> The contractor will be evaluated daily and if the contractor is
> considered to be substandard in the judgment of the supervisor, the
> contractor will initially receive notice of the problem from the
> supervisor and will be required to take corrective measures and to
> demonstrate improved performance.

C.  [Schedule]{.underline}

> > The contractor will perform studies for a minimum of 40 hours per
> > week, Monday through Friday. Failure to arrive on time or to follow
> > the time schedules or instructions as indicated shall be considered
> > default of the contract.
>
> [Reporting Requirements]{.underline}
>
> The contractor shall provide professional services for the Oral and
> Pharyngeal Cancer Branch, NIDCR during the period of August 29, 2007
> -- through -- August 28, 2008.
>
> The contractor will be paid a total of \$25,000..

**Justification**

> Attached is a request for \$25,000 to provide perdiem and travel for
> the services of Dr. Leelahavanichkul. Under this contract, Dr.
> Leelahavanichkul will provide services to the Oral and Pharyngeal
> Cancer Branch, (OPCB), NIDCR. Her contract will run from August 29,
> 2007 -- through -- August 28, 2008.
>
> Each year 40,000 Americans are diagnosed with cancer of the oral
> cavity, pharynx, or larynx, representing together nearly 5% of all
> diagnosed malignancies in the United States. Close to 10,000 U.S.
> patients are dying from oral cancer annually, exceeding the death
> rates for other better-known neoplastic diseases, including cervical
> cancer, malignant melanoma, and Hodgkin's disease. With more than
> 500,000 new cases per year worldwide, oral cancer is considered the
> sixth most common cancer in the developed world, and the vast majority
> of them are squamous cell carcinomas. Oral cancer is highly prominent
> in Thailand, and Dr. Leelahavanichkul has advanced training in
> molecular and cellular biology. She will use this knowledge to explore
> the molecular basis of skin and oral and pharyngeal cancer, and to
> evaluate the feasibility of using recently identified inhibitors to
> treat oral cancer patients. We expect this work will have a profound
> impact in our ability to battle this devastating disease that affects
> hundred of thousands of people around the world.
>
> The appointment of Dr. Leelahavanichkul is of critical importance to
> the success of these specific projects in the OPCB.